Yedan Chen
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.
Journal: Molecular oncology
Published: October 08, 2024
Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions.
Journal: BMC medicine
Published: September 15, 2024
Comprehensive genomic and clinical analyses identify APOBEC mutational signatures as a brain metastasis risk factor in lung adenocarcinoma patients.
Journal: Translational oncology
Published: November 20, 2023
Pathologic nodal metastasis assessment using tumour-derived molecular features in patients with lung adenocarcinoma.
Journal: Clinical and translational medicine
Published: September 05, 2023
Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial.
Journal: Cancer immunology, immunotherapy : CII
Published: April 20, 2022
Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial.
Journal: Clinical and translational medicine
Published: January 07, 2022
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.
Journal: Nature communications
Published: April 24, 2021
Genomic Profiling Identified Novel Prognostic Biomarkers in Chinese Midline Glioma Patients.
Journal: Frontiers in oncology
Published: September 17, 2020
Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.
Journal: Targeted oncology
Published: July 14, 2019
Showing 1-11 of 11
Last Updated: 09/26/2026